Prescribing is a complex skill required of doctors and, increasingly, other healthcare professionals. Use of a personal formulary can help to develop this skill. In 2006-9, we developed a core list of the 100 most commonly prescribed drugs. Our aim in the present study was to update this 'starter formulary' to ensure its continued relevance for prescriber training.
Introduction
In Outcomes for Graduates, the General Medical Council emphasizes the safe, effective and economical prescription of drugs as a core skill for all new UK medical graduates [1] . The importance of prescribing skills is further emphasized by the UK Prescribing Safety Assessment, which all new doctors must pass as a requirement of the Foundation Programme [2, 3] . Prescribing is a complex, multi-step process that includes defining the clinical problem and therapeutic objectives; identifying a suitable treatment; starting the treatment; giving appropriate information; and monitoring treatment success [4] . The challenge faced by trainee prescribers in acquiring this skill is compounded by the large number of drugs available. For example, in the UK, 1603 drugs and 18 408 preparations are licensed for prescription (personal communication, British National Formulary editorial team, October 2017).
To facilitate development and maintenance of prescribing competence, the World Health Organization (WHO) recommends that prescribers develop a list of 'P' drugs -a personal formulary of drugs that they prescribe regularly and can become familiar with [4] . This is difficult for undergraduate medical students who are not yet prescribing and who may see diverse practice as they rotate through healthcare settings and specialties. De Vries and colleagues found that provision of any formulary, whether learner or teacher-led, helped students to improve their prescribing skills [5] . In 2011, we therefore developed a 'starter formulary' of the 100 drugs most commonly prescribed in the UK from analysis of primary and secondary care prescribing data [6] . This helped students to focus their initial learning on drugs they would actually prescribe in practice and supported educators in developing learning resources and assessments [7] .
Our original list was developed from analysis of primary and secondary care prescribing data from 2006 to 2009. Over the last 5-10 years, there have been significant therapeutic advances, including the advent of direct oral anticoagulants and dipeptidyl peptidase 4 inhibitors. The aim of this study was to update the starter formulary by identifying the drugs most commonly prescribed in primary and secondary care in 2015, thereby supporting relevant modern-day learning for new prescribers.
Methods
Overview NHS prescription cost analysis (PCA) data was used to identify all items dispensed in the community in England in 2015 [8] . Electronic prescription records were used to identify all items prescribed in the University Hospital Birmingham NHS Foundation Trust in 2015. Medicinal products identified in each healthcare setting were formed into natural groups, guided by their classification in the British National Formulary (BNF) [9] . The most commonly prescribed drug groups in both or either setting were combined with drugs identified from emergency guidelines to generate the final core drug list.
Study approvals
This study did not require ethical approval as it was based wholly on aggregate data, with no linkage to patient-level data.
Data collection
Primary care. NHS PCA data for England 2015 was obtained. This is based on information obtained from prescriptions sent to the Prescription Pricing Division of the NHS Business Services Authority. All prescriptions dispensed in the community are included, the majority of which are written by general practitioners. Analysis was based on the frequency with which each medicinal product was dispensed.
Secondary care. A list of all items prescribed in University Hospital Birmingham NHS Foundation Trust in 2015 was obtained from their electronic prescribing system. Analysis was based on the frequency of medicinal product prescription.
Emergency drugs. A review of hospital guidelines generated a list of all emergency drugs used in hospital emergency settings [10] .
Compiling the core list camouflages, appliances and nutritional supplements). We also removed intravenous fluid preparations and vaccines because, although they fall within the definition of medicinal products, we judged that they represent educationally distinct groups. Finally, we planned to apply clinicaleducational judgement to remove drugs used in highly specialized practice that fell outside the scope of a core drug list for trainee prescribers.
The PCA data was used to develop natural drug groups. Medicinal products were first classified by BNF subparagraph. The products within each sub-paragraph were then classified by chemical name to identify and separate individual drug classes. Where several chemical entities fell naturally into a drug class, this was used as a group for analysis purposes. Conversely, where a chemical entity fell into a class of its own, it was named and analysed as such. For example, the BNF sub-paragraph 'Lipid-regulating drugs' was separated into statins, fibrates and ezetimibe. In a few cases, e.g. 'Nicotine replacement and related drugs', the BNF sub-paragraph was retained as the basis for the drug group. Where necessary, clinical judgement was applied to ensure groupings were natural and clinically applicable. The drug groups developed from the PCA data were then used to sort drugs in the secondary care data.
Compound products were not included as distinct items if their constituent ingredients were already captured in the top 100 list. Where different members of drug classes were used for more than one indication, the drug class was included only once (e.g. H 1 receptor antagonists for nausea and allergy) and the frequencies summed.
Prescribing frequency. For the PCA data, the number of items dispensed for all medicinal products within each drug group was summed and expressed as a percentage of the total number of items dispensed.
For the secondary care data, the number of prescriptions written for all medicinal products within each drug group was summed and expressed as a percentage of the total number of prescriptions.
Generating the top 100 drug list. Prior to the analysis, it was decided that the list would contain 100 drug groups as a number that was educationally attractive, sufficient to cover most prescribing by foundation doctors [6] and limited enough to be considered core.
Drug groups qualified for the top 100 list if they comprised ≥0.1% prescriptions in both primary and secondary care; ≥0.2% prescriptions in primary care but <0.1% prescriptions in secondary care; or ≥0.3% prescriptions in secondary care but <0.1% prescriptions in primary care. These definitions were chosen to optimize inclusion of drugs that were widely prescribed across healthcare systems and to reduce the inclusion of more specialist drugs, e.g. those with high use by a single specialist team in secondary care but not commonly prescribed by non-specialist doctors. As the number of drug groups meeting these criteria exceeded 100, clinical and educational judgement was used to review the less commonly prescribed drugs on these lists, selecting those considered to be prescribed by generalists over those requiring more specialist expertise. In addition, drugs from emergency guidelines that did not qualify by prescribing frequency but were considered to be clinically important were identified and room was made for them on the list by removing more specialist drugs.
Comparison of methodology between 2006-9 and 2015
Prescription cost analysis data was used to analyse items dispensed in the community in both 2006-9 and 2015 using broadly similar approaches. Minor changes in 2015 included a pre-planned decision to exclude intravenous fluids and vaccines from the analysis and to exclude combination products (e.g. analgesia, inhalers) from the final list where the constituent drugs were already included.
The main difference between studies was in the methods used to obtain the secondary care data. In 2006-9, a manual audit of paper drug charts of inpatients in two London hospitals was used to identify 7705 individual prescriptions. In 2015, a list of all (2.129 million) items prescribed that year in a single large teaching hospital was obtained from their electronic prescribing system. The 2015 secondary care data gives a much more comprehensive picture of secondary care prescribing, albeit from a single hospital with some distinct tertiary practice.
Results
The PCA 2015 dataset comprised 1.037 billion dispensed items, of which 24.775 million items were ineligible for inclusion ( Figure 1 ). The Birmingham hospital data set comprised 2.129 million prescriptions, of which 360 000 prescriptions were ineligible for inclusion. The primary and secondary care analysis datasets therefore comprised 1.013 billion items dispensed and 1.779 million prescriptions respectively.
Core drug list
Eighty-one drug groups that made up ≥0.1% items dispensed in primary care and prescriptions in secondary care comprised the majority of the list (Table 1) . Two drugs that met these criteria (nicorandil, 0.1% hospital prescriptions, 0.3% primary care items; hydroxychloroquine 0.1% hospital prescriptions, 0.1% primary care items) were considered more for specialist than generalist use and therefore not included in the final list.
All five drug groups that made up ≥0.2% items dispensed in primary care alone were included in the core drug list (Table 2 ). In addition, 'drugs for breast cancer', comprising 0.19% items dispensed) was included.
Eleven drug groups made up ≥0.3% prescriptions in secondary care alone and seven of these were included in the final list (Table 3 ). The four drug groups excluded from the core final list because they were considered to require more specialist than generalist expertise were N-methyl-D-aspartate receptor antagonists (e.g. ketamine), 1.9% prescriptions; immunosuppressants (e.g. tacrolimus, ciclosporin), 1.3% prescriptions; drugs for human immunodeficiency virus (HIV) infection (e.g. ritonavir), 1.1% prescriptions; and carbapenems (e.g. meropenem), 0.5% prescriptions.
Six drugs from emergency guidelines that did not qualify by prescribing frequency were considered clinically important and completed the list (Table 4) .
Changes in core drug list from 2006-2009 to 2015
There were 12 changes to the core list in 2015 from 2006-9 (Table 5) . Some of the drugs dropping out of the core drug list did so due to changes in qualification rules set in the prospectively defined analysis plan. Compound products were not included as distinct items if their constituent ingredients were already captured in the top 100 list (compound beta 2 agonist/corticosteroid inhalers; opioids, compound preparations). Where different members of drug classes were used for more than one indication, the drug class was included only once (anti-histamine anti-emetics and H 1 receptor antagonists were separate in the old list and combined in the new list). Vaccines and antisera were excluded because, although they fall within the definition of medicinal products, we judged that they were educationally distinct. Electrolytes Core drug list for prescribing training were split and analysed as their constituents (e.g. oral potassium, oral magnesium, intravenous electrolytes), which didn't individually make the list based on prescribing frequency.
Other drugs dropping out of the core list did so due to a fall in prescribing frequency relative to new entrants. These were anti-emetics, phenothiazines; dipyridamole; diuretics, potassium-sparing diuretics with other diuretics; laxatives, bulk forming, phenytoin and thiazolidinediones. Nicorandil was borderline for inclusion on the basis of prescribing frequency, but was excluded from the final list to make room for emergency medicines as it was judged more specialist than generalist compared to other borderline drugs.
All new entrants to the list qualified through an increase in relative prescribing frequency. For some drugs, this represents a genuine increase in use, e.g. direct oral anticoagulants, DPP-4 inhibitors, levetiracetam. For others, drug use may have remained constant but increased relative to some of those leaving the list (e.g. thiazolidinediones, phenytoin) where use has decreased.
Comparison of core drugs list to the World Health Organization list of essential medicines
The World Health Organization (WHO) compiles and updates a core list of minimum medicines required for a basic healthcare system and a complementary list of essential medicines for priority diseases where some specialist facilities, care or training are needed for their use [12] . Together these lists contain around 438 individual drugs. To determine the applicability of the core drug list to trainee prescribers working in healthcare systems outside England, we compared our list to the WHO list of essential medicines [12] . Seventy-eight per cent of our core drugs were on the WHO essential list and 4% were on the complementary list. Drugs not on the WHO list or on the complementary list only are shown in Table 6 . Table 4 Drugs identified from emergency guidelines not qualifying for the core list by prescribing frequency but considered to be core learning for new prescribers Drugs from emergency guidelines are in alphabetical order Table 5 Changes [6] . Reassuringly, only 12% of drugs in the list have changed, indicating that learning based on this resource could have long-term relevance for prescribing in practice. Some of the changes in the updated list reflect changes in qualification rules, such as removal of separate entries for compound preparations and drug groups used in more than one therapeutic area. Other changes, however, are likely to reflect genuine changes in prescribing guidelines and practice. For example, in 2010 the European Committee on Medicinal Products for Human Use recommended suspension of the marketing authorization of rosiglitazone, a thiazolidinedione, due to emerging evidence of cardiovascular risk [13] . Another thiazolidinedione, troglitazone, had previously been withdrawn from the British market in 1997 due to hepatotoxicity [14] . Although pioglitazone remains available for prescription and is still included in English guidelines produced by the National Institute for Health and Care Excellence (NICE) for the management of type 2 diabetes [15] , concerns about the safety of this drug class and adoption of alternatives, including the dipeptidyl peptidase-4 inhibitors (entering the list in 2015), likely account for the fall in thiazolidinedione prescribing. Another example is change in antiepileptic drug prescribing. Phenytoin, which was included in the 2006-9 list, was put on a 'potential signals of serious risks' list by the US Food and Drug Administration (FDA) in 2008 and is no longer recommended as either first line or adjunctive therapy for the prevention of any seizure type by NICE [16] . Carbamazepine and sodium valproate (in both old and new lists), as well as lamotrigine and levetiracetam (entering the list in 2015), are preferred. Phenytoin remains on the WHO List of essential medicines [12] and is still listed in NICE guidelines as adjunctive treatment to benzodiazepines for status epilepticus. There is therefore a case to include it in the top 100 list as an emergency drug. As trials seek to replace its use even for status epilepticus with safer alternatives [17] , we have made the judgement to leave it out of our list. Other educators and learners may wish to include it in theirs. Other changes in the list may be due to increasing disease prevalence or diagnosis. For example, increasing rates of diagnosis of dementia and prescription of anti-dementia drugs [18] could be responsible for the entry of acetylcholinesterase inhibitors to the list. Differences in data collection between the two analyses may also have had an effect. In 2006-9, secondary care prescribing data was collected by hand and so only included approximately 7500 prescriptions, whereas in 2015 use of electronic prescribing data allowed inclusion of nearly 1.8 million secondary care prescriptions.
Our list was developed using prescribing and dispensing data from England. To determine its relevance to an international audience, we reviewed it against the WHO essential and complementary medicines lists [12] . Over three quarters of drugs on our list are considered essential for a basic healthcare system and are therefore likely to be used worldwide. We considered the WHO list in its entirety (438 drugs) to be overwhelming for a beginner prescriber and feel that our core list has an important place in helping novice prescribers to direct most of their initial attention to the most commonly prescribed drugs.
A list of drugs to learn about perhaps seems an old fashioned concept in an era where healthcare education seeks to be patient-centred, integrated and problem-based, and curricula are moving to define and assess higher level competencies. Learning to prescribe is a complex process, well suited to a spiral curriculum where learners acquire understanding of the principles of clinical pharmacology, knowledge of drugs and therapeutics, and skills in prescribing in parallel, through multiple 'visits' to the topic of increasing complexity [19] . A core drug list gives trainee prescribers a tool to focus their acquisition of knowledge around drugs that they will use in early clinical practice. It allows them to build their learning from knowledge of the pharmacology of individual drugs, through understanding how these drugs are used in the management of common diseases to prescribing them in simulated, then real, clinical scenarios. The principles and skills developed can then be applied to unfamiliar drugs encountered in practice. A core drug list can also help educators to design useful learning resources [7] and assessments that are relevant to practice. For example, learners could be assessed not only on their knowledge of drugs on the core list, but also on their skills in information gathering to support safe prescribing of an unfamiliar drug.
Limitations
Our analysis has several limitations. The primary care data reflects English prescribing practice only, although we consider that it should be broadly representative of UK practice. With an appropriate overlay of local clinical-educational judgement, it may have broader generalizability. Our finding that over three quarters of drugs on the core list were also on the WHO essential medicines list supports this. Secondary care data was obtained from a single hospital, and may therefore be affected by local prescribing patterns, population characteristics, and specialist services. However, it is reassuring that the large majority of items on the list were prescribed frequently in both primary and secondary care, suggesting that most do not reflect specialist or centre-specific practice. Moreover, we applied clinical-educational judgement to exclude drugs considered to be mainly for specialist use and beyond the scope of a new prescriber.
The method of analysis and definition of drug groupings also had potential to influence the results. The complex process of screening BNF sub-paragraphs, classes and individual drugs requires some subjective judgement. However, this was informed by considerable experience of both clinical practice and prescriber training, aiming to produce educationally useful, clinically relevant groups. These are fully described so that educators using the list may also apply their own judgement.
Conclusion
Personal formularies are valuable tools to improve prescribing skills, but can be difficult to develop without help for the trainee prescriber. We have produced a core drug list of the most commonly prescribed drug groups in England to assist in this process. We consider that it should be generalizable to UK practice and -if supported by appropriate clinicaleducational judgement -more widely. Updating this formulary has resulted in 12 changes from 2006-9, keeping the list up to date with contemporary prescribing practice. This core drug list is not intended to restrict the scope of teaching or to stifle students' inquisitiveness. Rather, it should be considered as a 'starter formulary' to help novice prescribers to direct most of their early attention to the most commonly prescribed drugs.
